Prognostic characteristics and immune infiltration analysis of Kidney Renal Clear Cell Carcinoma based on m6A- associated lncRNA

Chen Chen,Xi Xiong,Jun J. Yang,Wei Zhang,Xiong Wang,Min Peng,Lili Li,Pengcheng Luo
DOI: https://doi.org/10.21203/rs.3.rs-2813868/v1
2023-01-01
Abstract:Abstract Background: The m6A mutation may have a significant effect on non-coding RNA metabolism, ultimately contributing to tumor growth and metastasis. However, the mechanism of m6A-related lncRNAs in Kidney Renal Clear Cell Carcinoma (KIRC) has not yet been elucidated. Methods: Herein, we used transcriptional and clinical data from the TCGA to conduct the comprehensive analysis of m6A-related prognostic lncRNAs in KIRC. Twelve lncRNAs correlated with m6A were shown to be strongly associated with clinical prognosis. We utilized consensus clustering to classify these prognostic lncRNAs into two groups based on their expression levels in tumor tissue. The cluster B was significantly associated with higher expression levels of m6A-related prognostic lncRNAs and shorter patient survival. Subsequently, seven m6A-related lncRNAs were recognized to structure a predictive model, which were strongly correlated with tumor prognosis and could be employed as the independent prognostic factor. In the analysis of clinical correlation, it was shown that risk score was remarkably related with tumor metastasis. Finally, our analysis established correlation between infiltrating immune cells and m6A-related lncRNAs in KIRC patients. Results: As a result, we investigated m6A-related lncRNAs and the prognosis of KIRC to reveal the relationship between the 530 clinical samples and 611 transcriptome data showed that the prognostic model established by 12 high-risk lncRNAs can predict KIRC. The prognosis of patients, among which seven key m6A-related lncRNAs: AC005261.3, AC024060.2, AC079174.2, AL139123.1, AL355388.1, CD27-AS1, and DGUOK-AS1, were significantly associated with the overall survival and prognosis of KIRC. Conclusion: Overall, our results imply that m6A-related prognostic lncRNAs could be underlying biomarkers for immunotherapy in KIRC.
What problem does this paper attempt to address?